The limitations of the study include the lack of data on prostate cancer screening history, as well as a lack of access to baseline and ongoing PSA measurements to assess the overlap between risk estimates derived from a high PRS or a high PSA test. The gene discussed is KLK3; the disease is prostate cancer.